In premenopausal women with breast cancer, triptorelin with chemotherapy reduced early menopause versus chemotherapy alone.
In plain wordsIn premenopausal women with breast cancer, triptorelin with chemotherapy reduced early menopause compared with chemotherapy alone.
- Outcome
- DecreaseEarly menopause at twelve months
- Study
n = 281
- Comparator
- Chemotherapy alone
- Analysis
- Primary
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 3.75 mg every 4 weeks · intramuscular · Duration of chemotherapyAs given in this study (human).
Measurements
- Early menopause
- 8.9%
- chemotherapy plus triptorelin
- Early menopause
- 25.9%
- chemotherapy alone
- Absolute difference
- −17%
- between groups
- Odds ratio
- 0.28
- treatment-related early menopause
Source sentences
Twelve months after the last cycle of chemotherapy (last follow-up, August 18, 2009), the rate of early menopause was 25.9% in the chemotherapy-alone group and 8.9% in the chemotherapy plus triptorelin group, an absolute difference of -17% (95% confidence interval, -26% to -7.9%; P < .001).
4 context sentences(design, population, supporting numbers)
The odds ratio for treatment-related early menopause was 0.28 (95% confidence interval, 0.14 to 0.59; P < .001).
The patients were premenopausal women with stage I through III breast cancer who were candidates for adjuvant or neoadjuvant chemotherapy.
Before beginning chemotherapy, patients were randomly allocated to receive chemotherapy alone or combined with triptorelin.
Triptorelin was administered intramuscularly at a dose of 3.75 mg at least 1 week before the start of chemotherapy and then every 4 weeks for the duration of chemotherapy.